Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer

• Main Authors: Zhongzhen Guan, Binghe Xu, Michelle L. Desilvio, Zhenzhou Shen, Wichit Arpornwirat, Zhongsheng Tong, Vicharn Lorvidhaya, Zefei Jiang, Junlan Yang, Anatoly Makhson, Wai Lim Leung, Mark W. Russo, Beth Newstat, Li Wang, George Chen, Cristina Oliva, Henry Gomez
• Format: Journal
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84880452171&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/52240
• Institution: Chiang Mai University

© 2013 by American Society of Clinical Oncology. Purpose: Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2). This study is designed to test whether the addition of lapatinib to paclitaxel improve...